Skip Navigation



Carcinogenesis Advance Access published online on May 21, 2008
Carcinogenesis, doi:10.1093/carcin/bgn115
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/7/1459    most recent
bgn115v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rodriguez, B. A.T.
Right arrow Articles by Huang, T. H.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, B. A.T.
Right arrow Articles by Huang, T. H.-M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Epigenetic Repression of the Estrogen-regulated Homeobox B13 Gene in Breast Cancer

Benjamin A.T. Rodriguez1, Alfred S.L. Cheng1,4, Pearlly S. Yan1, Dustin Potter1,3, Francisco J. Agosto-Perez1, Charles L. Shapiro2 and Tim H.-M. Huang1

1 Human Cancer Genetics Program
2 Department of Hematology andOncology, Comprehensive Cancer Center
3 Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, USA
4 Institute of Digestive Disease and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China

Request for reprints: Tim H.-M. Huang, Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Room 814, Biomedical Research Tower, 460 W. 12th Avenue, Columbus, OH 43210; Phone: 614-688-8277; Fax: 614-292-5995; E-mail: tim.huang{at}osumc.edu

Several studies have reported that a high-expression ratio of HOXB13 to IL17BR predicts tumor recurrence in node-negative, estrogen receptor (ER) {alpha}-positive breast cancer patients treated with tamoxifen. The molecular mechanisms underlying this dysregulation of gene expression remain to be explored. Our epigenetic analysis has found that increased promoter methylation of one of these genes, HOXB13, correlate with the decreased expression of its transcript in breast cancer cell lines (p < 0.005). Transcriptional silencing of this gene can be reversed by a demethylation treatment. HOXB13 is suppressed by the activation of estrogen signaling in ER{alpha}-positive breast cancer cells. However, treatment with 4-hydroxytamoxifen (4-OHT), an anti-estrogen, abrogates the ER{alpha}-mediated suppression in cancer cells. The notion that this transcriptional induction of HOXB13 occurs in vitro with simultaneous exposure to both estrogen and 4-OHT may provide a biological explanation for its aberrant expression in many node-negative patients undergoing tamoxifen therapy. Interestingly, promoter hypermethylation of HOXB13 is more frequently observed in ER{alpha}-positive patients with increased lymph node metastasis (p = 0.031) and large tumor sizes (>5 cm) (p = 0.008). In addition, this aberrant epigenetic event is associated with shorter disease-free survival (p = 0.029) in cancer patients. These results suggest that hypermethylation of HOXB13 is a late event of breast tumorigenesis and a poor prognostic indicator of node-positive cancer patients.

Received March 14, 2008; revised April 29, 2008; accepted May 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P.-Y. Hsu, D. E. Deatherage, B. A.T. Rodriguez, S. Liyanarachchi, Y.-I Weng, T. Zuo, J. Liu, A. S.L. Cheng, and T. H-M. Huang
Xenoestrogen-Induced Epigenetic Repression of microRNA-9-3 in Breast Epithelial Cells
Cancer Res., July 15, 2009; 69(14): 5936 - 5945.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.